Skip to content
IMMXImmix Biopharma, Inc.

Earnings

When Immix Biopharma, Inc. reports, what it reported each quarter, and how the stock took the results.

23 quarters. Mar 31, 2021 to Sep 30, 2026. mixed units.

Next results · Q4 2026Projected

10-K due Mar 22 – Apr 2

No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 5 filings.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 22 – Apr 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Net income
-$10.65M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026-$13.93MNo Q3 2025 on file

Latest results

  1. Q3 2026Nov 12, 2026, after the closeThe release
    Revenue
    —
    —
    Net income
    -$13.93M
    N/M
    EPS
    -$0.19
    N/M
    On November 12, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for its quarter ended September 30, 2026.
  2. Q2 2026Aug 7, 2026, after the close+4.2%by the close of Aug 10
    Revenue
    —
    —
    Net income
    -$11.56M
    N/M
    EPS
    -$0.18
    N/M
  3. Q1 2026May 7, 2026, after the close+2.2%by the close of May 8
    Revenue
    —
    —
    Net income
    -$10.09M
    N/M
    EPS
    -$0.18
    N/M
  4. Q4 2025Mar 25, 2026, after the close2.0%by the close of Mar 26
    Revenue
    —
    —
    Net income
    -$10.65M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 12, 2026 · after-hoursNov 12, 202643 d10-Q——-$0.19—
Q2 2026Jun 30, 2026—Aug 7, 202638 d10-Q——-$0.18+4.2%
Q1 2026Mar 31, 2026—May 7, 202637 d10-Q——-$0.18+2.2%
FY 2025
Q4 2025derivedDec 31, 2025—Mar 25, 202684 d10-K———2.0%
Q3 2025Sep 30, 2025—Nov 7, 202538 d10-Q——-$0.24+2.8%
Q2 2025Jun 30, 2025—Aug 8, 202539 d10-Q——-$0.223.4%
Q1 2025Mar 31, 2025—May 8, 202538 d10-Q——-$0.154.5%
FY 2024
Q4 2024derivedDec 31, 2024—Mar 25, 202584 d10-K———+3.4%
Q3 2024Sep 30, 2024—Nov 12, 202443 d10-Q——-$0.249.3%
Q2 2024Jun 30, 2024—Aug 12, 202443 d10-Q——-$0.15—
Q1 2024Mar 31, 2024—May 9, 202439 d10-Q——-$0.22—
Earlier years, FY 2021 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 12, 2026051383
10-QAug 7, 2026036643
10-QMay 7, 2026021764
10-KMar 25, 2026012714
10-QNov 7, 2025021325
10-QAug 8, 2025022829
10-QMay 8, 2025009280
10-KMar 25, 2025000387
10-QNov 12, 2024044787
10-QAug 12, 2024031358

Provenance

ProvenanceData status and checks

Immix Biopharma, Inc. · CIK 1873835 · Engraved from SEC EDGAR